Brief: Arrowhead Seeks Approval to Begin ARO-MAPT Alzheimer’s Trial
10/09/2025 12:31
Sept 10 (Reuters) - Arrowhead Pharmaceuticals Inc ARWR.O: ARROWHEAD PHARMACEUTICALS REQUESTS REGULATORY CLEARANCE TO INITIATE PHASE 1/2A STUDY OF ARO-MAPT FOR THE TREATMENT OF ALZHEIMER’S DISEASE AND OTHER TAUOPATHIES Source text: ID:nBw52pHdXa Further company coverage: ARWR.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Arrowhead Pharmaceuticals
See all newsBrief: Uk's MHRA Authorises Redemplo For Adults With Familial Chylomicronaemia Syndrome
US STOCKS ON THE MOVE-Netflix, Coinbase Global, Accenture
US STOCKS ON THE MOVE-Bending Spoons, Skydance, Albertsons
US STOCKS ON THE MOVE-Albertsons, GlobalFoundries, American Electric Power, Fastenal
Brief: Arrowhead Pharmaceuticals Announces ARO-MAPT Interim Phase 1/2a Clinical Data Demonstrating Deep and Durable Tau Reductions in Healthy Volunteers